Search

MSK experts have conducted the first large-scale study focused specifically on burnout among practicing anesthesiologists in the United States.

… Monday, April 19, 2021 MSK anesthesiologist Anoushka Afonso, MD , and Joshua Cadwell, GME medical student summer fellowship program alumni, partnered with colleagues from Boston Children’s Hospital and Harvard Medical School, to conduct the first large-scale study focused specifically on burnout among

To recognize the beginning of Breast Cancer Awareness Month, MSK shared five tips to help women navigate the prevention, diagnosis, and treatment of breast cancer during the COVID-19 global health crisis.

… Wednesday, September 30, 2020 Dr. Larry Norton Dr. Larry Norton To recognize the beginning of Breast Cancer Awareness Month, Memorial Sloan Kettering Cancer Center (MSK) today shared five tips to help women navigate the prevention, diagnosis, and treatment of breast cancer during the COVID-19 global

Para destacar el inicio del Mes de Concientización del Cáncer de Mama, MSK compartió cinco consejos para ayudar a las mujeres a manejar la prevención, el diagnóstico y el tratamiento del cáncer de mama durante la crisis de salud mundial ocasionada por el COVID-19.

… Wednesday, September 30, 2020 Dr. Larry Norton Dr. Larry Norton Para destacar el inicio del Mes de Concientización del Cáncer de Mama, Memorial Sloan Kettering Cancer Center (MSK) compartió cinco consejos para ayudar a las mujeres a manejar la prevención, el diagnóstico y el tratamiento del cáncer de

MSK researchers have found that a protein that contributes to one type of leukemia when it’s missing can lead to the formation of a different leukemia type when it’s present.

… Wednesday, November 21, 2018 Summary MSK researchers have found that Helios — a protein named after the Greek sun god — contributes to one type of leukemia when it’s missing but can lead to the formation of a different leukemia type when it’s present. Proteins are one of the fundamental building blocks

… Wednesday, November 24, 2021 Updates 9/2/25: Dr. Bott, pathologist Marina Baine, MD, PhD , and i nterventional pulmonologist Or Kalchiem-Dekel, MD , recently led the first study to evaluate the yield and accuracy of ssRAB-obtained biopsy specimens across all stages of lung cancer. The retrospective review

Despite the proven benefits of exercise, even while receiving cancer treatment, new research undertaken by Memorial Sloan Kettering’s Integrative Medicine Service, shows that the majority of cancer patients report significant decreases in their physical activity levels after their cancer diagnosis.

… Wednesday, February 15, 2017 Despite the proven benefits of exercise, even while receiving treatments, new research from Memorial Sloan Kettering’s Integrative Medicine Service shows that the majority of cancer patients report significant decreases in their physical activity levels after their cancer

A prototype of an innovative device developed at Memorial Sloan Kettering for minimally invasive surgery in head, neck, and other cancers in confined spaces holds promise for helping patients around the globe.

… Thursday, December 1, 2011 Summary A prototype of an innovative device developed at Memorial Sloan Kettering for minimally invasive surgery in head, neck, and other cancers in confined spaces holds promise for helping patients around the globe. An expert on minimally invasive laser surgery, Snehal G.

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce Selwyn M. Vickers, MD, President and CEO of MSK, is among 30 international scientific leaders elected today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy class of 2024.

… Friday, January 12, 2024 Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce Selwyn M. Vickers, MD, President and CEO of MSK, is among 30 international scientific leaders elected today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy class of 2024

Investigators found that olaparib extended progression-free survival by an average of three months in women with advanced breast cancer.

… Sunday, June 4, 2017 Summary A new trial of olaparib found that the drug extended progression-free survival by an average of three months in women with advanced breast cancer . Olaparib is in a class of drugs called PARP inhibitors. Update: On January 12, 2018 the FDA approved olaparib (Lynparza®) for

The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever drug approved for ECD, a rare blood disorder. This landmark approval came as a direct result of research at Memorial Sloan Kettering Cancer Center (MSK).

… Monday, November 6, 2017 Bottom Line The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600 -mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever